TVGN logo

TEVOGEN INC

TVGNNASDAQ
🏆 #4659 by market capEarnings Nov 13US Equity
$6.75▼ $0.01 (−0.15%)
🌙 After hours$6.75▲ 0.00%Regular close · extended-hours price shown
🔔
Track TVGN
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.1%
7d▼ 11.6%
14d▼ 12.3%
30d▲ 7.0%
ytd▼ 59.3%
1y▼ 82.8%
🏦Market Cap
$28M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
84
Good

Trading Snapshot

Day Range
$6.68 – $6.83
52-Week Range
$3.64 – $40.45
Volume
$3.66B
Avg Volume
$3.80B
Shares Outstanding
4.2M
Next Earnings
Dec 1, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$806,244
P/E Ratio
-1.2
P/S Ratio
0.0x
EPS (TTM)
$-5.64
Dividend Yield
0.00%
Dilution (1yr)
−6.7%

Why Investors Own TVGN

  • ✓High-growth profile — revenue up +30.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 38% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TVGN logo

TEVOGEN INC

TVGN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$26M▼ −51.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12M▲ +3.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.3M▼ −6.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$3M▼ −$946K YoY
StockOtter · stockotter.space

About TEVOGEN INC

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$7.12
▲ +5.5% Upside
High Target$8.56
Low Target$6.40
Based on 30 analysts

Latest News & Updates

GlobeNewsWire·Jul 29

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Direc

GlobeNewsWire·Jul 13

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is scheduled for Monday, Aug